Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1952 1
1953 3
1954 3
1956 1
1957 1
1958 1
1959 1
1964 1
1967 2
1971 1
1973 4
1975 1
1977 1
1978 1
1979 1
1980 2
1981 2
1982 3
1983 2
1984 6
1985 3
1986 6
1987 3
1988 5
1989 2
1990 7
1991 4
1992 6
1993 5
1994 7
1995 4
1996 12
1997 6
1998 13
1999 11
2000 10
2001 11
2002 7
2003 9
2004 18
2005 13
2006 13
2007 18
2008 16
2009 11
2010 14
2011 15
2012 14
2013 19
2014 14
2015 16
2016 16
2017 15
2018 24
2019 20
2020 27
2021 31
2022 23
2023 29
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for astatine
Search for astatin instead (2 results)
Astatine.
Meyer GJ. Meyer GJ. J Labelled Comp Radiopharm. 2018 Mar;61(3):154-164. doi: 10.1002/jlcr.3573. Epub 2018 Feb 22. J Labelled Comp Radiopharm. 2018. PMID: 29080397 Review.
The half-lives of its longest living isotopes (210) At and (211) At with 8.3 and 7.22 hours respectively together with their alpha decay characteristics made these isotopes interesting for radiation biological research. However, the lack of stable isotopes of astatine pres …
The half-lives of its longest living isotopes (210) At and (211) At with 8.3 and 7.22 hours respectively together with their alpha decay cha …
Astatine-211 based radionuclide therapy: Current clinical trial landscape.
Albertsson P, Bäck T, Bergmark K, Hallqvist A, Johansson M, Aneheim E, Lindegren S, Timperanza C, Smerud K, Palm S. Albertsson P, et al. Front Med (Lausanne). 2023 Jan 6;9:1076210. doi: 10.3389/fmed.2022.1076210. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36687417 Free PMC article. Review.
Astatine-211 ((211)At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). ...
Astatine-211 ((211)At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particl …
Astatine-211: production and availability.
Zalutsky MR, Pruszynski M. Zalutsky MR, et al. Curr Radiopharm. 2011 Jul;4(3):177-85. doi: 10.2174/1874471011104030177. Curr Radiopharm. 2011. PMID: 22201707 Free PMC article. Review.
The 7.2-h half life radiohalogen (211)At offers many potential advantages for targeted alpha-particle therapy; however, its use for this purpose is constrained by its limited availability. Astatine-211 can be produced in reasonable yield from natural bismuth targets via th …
The 7.2-h half life radiohalogen (211)At offers many potential advantages for targeted alpha-particle therapy; however, its use for this pur …
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E. Lindegren S, et al. Cancer Biother Radiopharm. 2020 Aug;35(6):425-436. doi: 10.1089/cbr.2019.3055. Epub 2020 Feb 20. Cancer Biother Radiopharm. 2020. PMID: 32077749 Free PMC article. Review.
Despite the consensus around the clinical potential of the alpha-emitting radionuclide astatine-211 ((211)At), there are only a limited number of research facilities that work with this nuclide. ...Despite a relatively large number of globally existing cyclotrons capable o …
Despite the consensus around the clinical potential of the alpha-emitting radionuclide astatine-211 ((211)At), there are only a limit …
[(211)At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies.
Laszlo GS, Sandmaier BM, Kehret AR, Orozco JJ, Hamlin DK, Dexter SL, Lim SYT, Cole FM, Huo J, Wilbur DS, Walter RB. Laszlo GS, et al. Leuk Lymphoma. 2023 Jul-Aug;64(7):1335-1339. doi: 10.1080/10428194.2023.2210710. Epub 2023 May 11. Leuk Lymphoma. 2023. PMID: 37170642 No abstract available.
Basis for the ICRP's updated biokinetic model for systemic astatine.
Leggett R, Samuels C. Leggett R, et al. J Radiol Prot. 2022 Feb 1;42(2). doi: 10.1088/1361-6498/ac48e2. J Radiol Prot. 2022. PMID: 34991086 Review.
The International Commission on Radiological Protection (ICRP) recently updated its biokinetic models for workers in a series of reports called the OIR (occupational intakes of radionuclides) series. A new biokinetic model for astatine (At), the heaviest member of the halo …
The International Commission on Radiological Protection (ICRP) recently updated its biokinetic models for workers in a series of reports cal …
Enigmatic astatine.
Wilbur DS. Wilbur DS. Nat Chem. 2013 Mar;5(3):246. doi: 10.1038/nchem.1580. Nat Chem. 2013. PMID: 23422568 No abstract available.
517 results